07Oct
06Oct
eSight Announces New Partnership with Merlin Entertainments to Change Lives Around The World
Leading vision-enhancement platform, eSight, announces a new partnership with Merlin Entertainments, one of the largest attractions operators in the world. Together, the companies will provide multiple life-changing experiences for individuals with vision impairment. In addition, eSight and Merlin will work together to create more inclusive initiatives for future guests with low vision or legal blindness. eSight and Merlin Entertainments are working together to create once-in-a-lifetime experiences at Merlin Entertainments' LEGOLAND® Parks, LEGOLAND® Discovery Center and SEA LIFE locations. Read more...
05Oct
Brain injury therapy advancing toward human studies
Research that began at The University of Texas Health Science Center at San Antonio 15 years ago is nearing a significant milestone: human testing of an intravenous (IV) drug to treat brain injuries such as concussion and stroke. The implications are enormous. A therapy for soldiers on the battlefield, car crash victims, concussed football players and people who suffer strokes could ease the pain and suffering of thousands worldwide daily and prevent debilitating long-term effects of traumatic brain injury. Astrocyte Pharmaceuticals is...
05Oct
VC funding update: Which Boston startups made bank in September
Boston's startups and tech companies were busy in September, pulling in collective billions from VCs and other investors. Here's who raised and what they pulled in: Watertown-based pharmaceutical company Windgap Medical Inc. raised more than $17M in equity. Read more >>
30Sep
Centivo and CleanFiber headline Buffalo startups that raised money this summer – Buffalo Business First
Buffalo-based startups kept up a robust pace of funding rounds this summer, at least by local standards. Here is a roundup of the companies that completed funding rounds over the past few months...Read more >>
30Sep
2021 U.S. COHORT & COMPETITION FINALISTS – MassChallenge’s 50th Accelerator Program
At MassChallenge, we support uncommon founders with an uncommon model. Our community-powered accelerator provides high-potential startups with the accountability, expertise and network they need to accelerate towards the next critical milestone. Each year, MassChallenge’s accelerator includes a competition in which startups from each cohort may compete for non-equity cash prizes. Today we are excited to announce the 45 startups that have qualified to compete in our final judging process for $1M in non-equity prizes. SCRIBLE is one of the Competition...
30Sep
FDA Created New Category for ZetrOZ’s Long-Duration Pain Management Ultrasound Device
ZetrOZ System's Sustained Acoustic Medicine (sam®) device, the only FDA-cleared device of its kind, is part of a new category established by the U.S. Government for the novel device's wearable, long-duration ultrasound therapy for home use. A Class II medical device initially cleared by the FDA in 2013, sam® was later provided with expanded indications in 2020. It is the only home-use, long-duration ultrasound treatment for reducing pain and improving circulation to heal soft tissue injuries. Read more >>
30Sep
Enrich Therapeutics develops desktop cell isolation system for therapeutic discovery
Enrich Therapeutics is developing a desktop static cell isolation technology that can separate clones to accelerate therapeutic discovery. We spoke with Dong Wang, who is co-founder, president, and chief operating officer of Enrich Therapeutics, as part of our coverage of the competition. Read more >>
30Sep
The Next COVID Challenge: Building an Arsenal of Vaccines
For months, international partners have pressured the United States about intellectual property (IP) concerns and access to SARS-CoV-2 vaccines. As the country emerges from the worst of the pandemic, President Joe Biden now has an opportunity to shift his administration’s focus to realizing its longstanding promise of making the United States “the arsenal of vaccines for the world” (1). However, the country cannot accomplish that goal just by exporting mRNA vaccines and waiving IP protections. The current generation of vaccines...
29Sep